MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Topic
Antiplatelet Therapy and Cardiovascular Diseases
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

1,498 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
1,498 works in the cohort · of 4,299,418page 9 of 30

Labels cover 9 of 1,498 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 1,498 of 1,498 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affno abstractunlabeled
Long-term outcomes for women versus men with unstable angina/non–ST-segment elevation myocardial infarction managed medically without revascularization: Insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes trial
Peter Clemmensen, Matthew T. Roe, Judith S. Hochman, Derek D. Cyr, Megan L. Neely, Darren K. McGuire +8 more
2015· article· en· American Heart Journal· Medicine
machine prediction:candidate · noneconsensus · none
23
citations
afffundunlabeled
Clopidogrel Use in End‐Stage Kidney Disease
Bassem Y. Tanios, Houssam S. Itani, Deborah Zimmerman
2014· review· en· Seminars in Dialysis· Medicine
machine prediction:candidate · noneconsensus · none
22
citations
afffundunlabeled
Ischemic and bleeding outcomes after coronary artery bypass grafting among patients initially treated with a P2Y<sub>12</sub> receptor antagonist for acute coronary syndromes: Insights on timing of discontinuation of ticagrelor and clopidogrel prior to surgery
Juan Russo, Tyler E. James, Marc Ruel, Jean‐Yves Dupuis, Kuljit Singh, Daniel Goubran +13 more
2018· article· en· European Heart Journal Acute Cardiovascular Care· Medicine
machine prediction:candidate · noneconsensus · none
22
citations
affunlabeled
The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial
Masafumi Ono, Ply Chichareon, Mariusz Tomaniak, Hideyuki Kawashima, Kuniaki Takahashi, Norihiro Kogame +23 more
2020· article· en· Clinical Research in Cardiology· Medicine
machine prediction:candidate · noneconsensus · none
22
citations
fundno affno abstractunlabeled
Aspirin twice a day keeps new COX‐1 at bay
Marie Lordkipanidzé, Paul Harrison
2012· letter· en· Journal of Thrombosis and Haemostasis· Medicine
machine prediction:candidate · noneconsensus · none
22
citations
affno abstractunlabeled
Xarelto plus Acetylsalicylic acid: Treatment patterns and Outcomes in patients with Atherosclerosis (XATOA): Rationale and design of a prospective registry study to assess rivaroxaban 2.5 mg twice daily plus aspirin for prevention of atherothrombotic events in coronary artery disease, peripheral artery disease, or both
Keith A.A. Fox, Sonia S. Anand, Victor Aboyans, Martín Cowie, E. Sebastian Debus, Uwe Zeymer +4 more
2020· article· en· American Heart Journal· Medicine
machine prediction:candidate · noneconsensus · none
21
citations
afffundno abstractunlabeled
Molecular basis of platelet granule defects
Walter H.A. Kahr
2024· review· en· Journal of Thrombosis and Haemostasis· Medicine
machine prediction:candidate · noneconsensus · none
20
citations
20
citations

How this was built: Screen · Findings · About